It’s wonderful news for those with HER2 positive (HER2+) advanced breast cancer (ABC) that Pharmac proposes to fund Enhertu (trastuzumab deruxtecan, T-DXd), a breakthrough HER2-targeted medicine, from 1st January 2025.
Enhertu has been shown to keep HER2+ ABC disease stable four times longer than current treatments, and results in a longer survival time. This time is precious for New Zealand women with breast cancer and we’re delighted to see that Enhertu will be funded.
One of the biggest challenges in any diagnosis, and treatment journey, is finding positivity during very worrying and difficult times.
BCAC recently joined over twenty groups representing New Zealanders with a wide range of diseases to visit Wellington under the Patient Voice Aotearoa (PVA) banner. We met Hon. Dr Ayesha Verrall, Labour’s health spokesperson and former Health Minister, and visited Pharmac to hear Hon. David Seymour, Associate Health Minister (Pharmac) present his Letter of Expectation to Hon. Paula Bennett, Pharmac’s recently appointed Board Chair.
Good news for New Zealanders with advanced triple negative breast cancer. From 1st October 2024 Pharmac will fund Keytruda (pembrolizumab) for those with recurrent or metastatic triple negative breast cancer. Around 15% of all breast cancers, and 16% of metastatic breast cancers, are classified as triple negative.
Difficulty concentrating or forgetfulness experienced by some people during and after breast cancer treatment is known as brain fog or chemo brain. Researchers at Auckland University want to understand whether there are changes in the brain caused by cancer or its treatment. Better understanding will lead to improved management of this condition in future patients.
This webinar is a comprehensive, in-depth presentation by NZ medical experts that answers questions about pain and its management from NZ women with advanced breast cancer.
‘We recommend this for anyone with questions about pain and pain management. It provides a lot of valuable information about pain in general and pain associated with breast cancer and its treatment.’ says BCAC Chair Libby Burgess.
Dear Prime Minister Christopher Luxon, Minister of Finance Nicola Willis, and Associate Minister of Health (Pharmac) David Seymour.
In August last year a promise was made to fund 13 new cancer medicines via a $280 million ring-fenced fund to Pharmac. According to the National election manifesto, that fund was to start on July 1 this year by reinstating the $5 prescription fee. As you stated Prime Minister, those 13 medicines are "for lung, bowel, kidney, melanoma, and head and…
Have you undergone chemotherapy for cancer for the first time in the last twelve months? Researchers from The University of Sydney are interested in your experience. Participants over 18 are wanted to complete a 20-25 minute online survey.
Breast cancer organisations turned out in force at Valuing Life, a Parliamentary Medicines Access Summit. We all did our best to make the case for broader, faster access to modern medicines to improve the lives of breast cancer patients.
Good news for New Zealanders with advanced hormone receptor positive HER2 negative breast cancer. From 1st July Pharmac will fund Kisqali (ribociclib) for those who haven’t previously had funded access to Ibrance (palbociclib). BCAC asked Novartis to provide Kisqali free to patients until Pharmac funding kicks in and they agreed. So, if you’re starting or continuing on Kisqali you won’t have to pay medicine costs from now onwards.
